Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as vudalimab
vudalimab+ carboplatin+ cabazitaxel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A - AVPCa | EXPERIMENTAL | - |
| Cohort B - HRD/CDK12 PARP - Progressors | EXPERIMENTAL | - |
| Cohort C - HRD/CDK12 PARP Naïve | EXPERIMENTAL | - |
| Cohort D - MSI-H, MMRD or TMB-H | EXPERIMENTAL | - |
| Cohort E - No Targetable Mutations | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vudalimab + carboplatin + cabazitaxel | COMBINATION_PRODUCT | Vudalimab IV, carboplatin IV, cabazitaxel IV |
| vudalimab + olaparib | COMBINATION_PRODUCT | Vudalimab IV, olaparib oral |
| vudalimab monotherapy | BIOLOGICAL | Vudalimab IV |
| vudalimab + docetaxel | COMBINATION_PRODUCT | Vudalimab IV, docetaxel IV |
| vudalimab + cabazitaxel or docetaxel | COMBINATION_PRODUCT | Vudalimab IV, cabazitaxel or docetaxel IV |
Inclusion Criteria: * Able to provide written informed consent * Adult (age ≥ 18 years) * Histologically confirmed diagnosis of carcinoma of the prostate * Documented progressive mCRPC based on at least one of the following criteria: * PSA progression, defined as at least 2 rises in PSA with a m...
Vudalimab is an investigational monoclonal antibody being studied for the treatment of ovarian cancer and metastatic castration-resistant prostate cancer. It is also being evaluated in other gynecologic and genitourinary malignancies, including clear cell carcinoma, endometrial cancer, and cervical carcinoma.
Vudalimab is a monoclonal antibody, classified as a -mab antibody. It is being developed by Xencor, Inc. for use in oncology indications, including ovarian cancer and metastatic castration-resistant prostate cancer.
Vudalimab is being developed by Xencor, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XNCR. The company is conducting clinical trials of vudalimab in patients with advanced gynecologic and genitourinary malignancies.
Vudalimab is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials have been conducted, one of which is completed and the other is active but not recruiting participants.
Vudalimab is being studied in two Phase 2 clinical trials. NCT05005728 is a completed study in patients with metastatic castration-resistant prostate cancer. NCT05032040 is an active study in patients with ovarian cancer, clear cell carcinoma, endometrial cancer, cervical carcinoma, and metastatic castration-resistant prostate cancer.
Yes, vudalimab is also known as XmAb20717. Clinical trials refer to the drug by this alternative name, including NCT05005728 and NCT05032040, which study vudalimab in patients with advanced gynecologic and genitourinary malignancies.